Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study

• Published in: PloS one Vol. 11; no. 4; p. e0154221
• Main Authors: Teeranaipong, Phairote, Sirivichayakul, Sunee, Mekprasan, Suwanna, Ohata, Pirapon June, Avihingsanon, Anchalee, Ruxrungtham, Kiat, Putcharoen, Opass
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 27.04.2016; Public Library of Science (PLoS)
• Subjects: Acquired immune deficiency syndrome; Adult; AIDS; Anti-HIV Agents - therapeutic use; Antiretroviral agents; Antiretroviral drugs; Benzoxazines - therapeutic use; Biology and Life Sciences; Cross-Sectional Studies; Dosage and administration; Drug resistance; Drug Resistance, Viral; Earth Sciences; Efavirenz; Etravirine; Failure analysis; Female; HIV; HIV Infections - drug therapy; HIV Infections - epidemiology; HIV Reverse Transcriptase - antagonists & inhibitors; HIV Reverse Transcriptase - genetics; HIV-1 - drug effects; HIV-1 - genetics; Human immunodeficiency virus; Humans; Male; Medicine and Health Sciences; Mutation; Nevirapine; Nevirapine - therapeutic use; Patients; People and Places; Protease inhibitors; Pyridazines - therapeutic use; Rams; Research and Analysis Methods; Reverse Transcriptase Inhibitors - therapeutic use; Rilpivirine; Rilpivirine - therapeutic use; Sampling methods; Scoring; Social Sciences; Thailand - epidemiology; Viral Load - drug effects; Young Adult; Thailand; Netherlands; Australia; United States > US; Bangkok Thailand
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0154221

Etravirine(ETR) can be used for patients who have failed NNRTI-based regimen. In Thailand, ETR is approximately 45 times more expensive than rilpivirine(RPV). However, there are no data of RPV use in NNRTI failure. Therefore, we assessed the susceptibility and mutation patterns of first line NNRTI failure and the possibility of using RPV compared to ETV in patients who have failed efavirenz(EFV)- and nevirapine(NVP)-based regimens. Clinical samples with confirmed virological failure from EFV- or NVP-based regimens were retrospectively analyzed. Resistance-associated mutations (RAMs) were interpreted by IAS-USA Drug Resistance Mutations. Susceptibility of ETR and RPV were interpreted by DUET, Monogram scoring system, and Stanford University HIV Drug Resistance Database. 1,279 and 528 patients failed EFV- and NVP-based regimens, respectively. Y181C was the most common NVP-associated RAM (54.3% vs. 14.7%, p<0.01). K103N was the most common EFV-associated RAM (56.5% vs. 19.1%, P<0.01). The results from all three scoring systems were concordant. 165(11.1%) and 161(10.9%) patients who failed NVP-based regimen were susceptible to ETR and RPV, respectively (p = 0.85). 195 (32.2%) and 191 (31.6%) patients who failed EFV-based regimen, were susceptible to ETR and RPV, respectively (p = 0.79). The susceptibility of ETV and RPV in EFV failure was significantly higher than NVP failure (p<0.01). The mutation patterns for ETR and RPV were similar but 32% and 11% of patients who failed EFV and NVP -based regimen, respectivly were susceptible to RPV. This finding suggests that RPV can be used as the alternative antiretroviral agent in patients who have failed EFV-based regimen.